Cell Therapy CDMO in Japan
AGC Biologics is one of the top CDMOs for cell and gene therapies and holds an impressive track record. By expanding our cell therapy services into Japan, we are extending our capabilities and can now offer services in both Europe and Asia, enabling patients to access these life-changing medicines quickly.
The AGC Yokohama Technical Center is currently providing cell therapy process development services while our new facility comes online. Once operational, the new building will provide process transfer, development, cell manipulation, and engineering services using the autologous and allogeneic processes developed at our Center of Excellence in Milan.
Got a project? Let's talk.
Mammalian Cell Culture Manufacturing
This site will soon offer one of the largest single-use bioreactors for a CDMO in Japan as we expand to meet growing demand in the APAC region. This site will extend our already impressive global network for protein biologics and single-use technology.
Mammalian process development services are also available at our nearby site in Chiba. Projects can be easily transferred to the Yokohama facility for GMP manufacturing starting in 2027.
The new facility will also benefit from close collaboration with the 1,000+ scientists at the AGC Yokohama Technical Center and the AGC Biologics facility in Chiba, Japan.
Ready to learn more?
mRNA Production Services
AGC Biologics Yokohama facility will be equipped for mRNA services, expanding our capacity across two sites in Europe and Asia. This new facility will have two IVT lines, purification lines, and lipid nanoparticle (LNP) lines to allow for seamless production up to 50g of mRNA using single-use technology.
Proprietary plasmid DNA supply and proven processes from our Heidelberg facility ensure we have everything you need for your next project.
Ready to learn more?
Get all the details on this site
Our in-depth fact sheet provides all the details you need on the complete capabilities and services of this campus and its abilities to support your next project.
Yokohama fact sheetMammalian Manufacturing
We will offer one of the largest single-use bioreactors for a CDMO in Japan with multiple 5,000 L and 2,000 L bioreactors for mammalian cell culture.
Cell Therapy Manufacturing
This facility will offer capabilities for gene modification of cells by LVV/RVV and provide both autologous and allogeneic methods with GMP manufacturing coming soon.
Global Capabilities
Messenger RNA Manufacturing
The new Yokohama facility is set to begin GMP mRNA manufacturing in 2027. It will feature clinical to commercial production, as well as multiple purification and lipid nanoparticle (LNP) lines. This facility will benefit from shared best practices and decades of expertise drawn from our Heidelberg mRNA facility.
Process Development
Cell therapy process development services are available now at our AGC Yokohama Technical Center. Mammalian process development services are available at our Chiba facility. Full PD services, including mRNA, coming soon.
